PSP Liquid-Liquid Phase Separation and Biomolecular Condensates
Definition: Liquid-liquid phase separation (LLPS) is a thermodynamic process by which proteins and nucleic acids demix from the aqueous cellular environment to form membrane-less organelles called biomolecular condensates or droplets. These liquid-like assemblies concentrate specific molecular components while excluding others, creating functional microcompartments for biochemical reactions.
Overview
In progressive supranuclear palsy (PSP), LLPS has emerged as a critical mechanism linking stress granule pathology to tau aggregation. The 4R-tau pathology characteristic of PSP demonstrates particularly strong associations with stress granule dysfunction and condensate-mediated nucleation events. This page synthesizes the evidence connecting phase separation biology to PSP pathogenesis, covering molecular mechanisms, cellular pathology, biomarker potential, and therapeutic implications.
Molecular Mechanisms of LLPS in PSP
Tau Intrinsic Propensity for Phase Separation
Tau protein possesses multiple features that favor phase separation:
Prion-Like Domain Properties: The N-terminal projection domain of tau contains low-complexity sequences that facilitate weak multivalent interactions necessary for LLPS. The microtubule-binding repeat domain (MTBD) contributes additional interaction surfaces.
...PSP Liquid-Liquid Phase Separation and Biomolecular Condensates
Definition: Liquid-liquid phase separation (LLPS) is a thermodynamic process by which proteins and nucleic acids demix from the aqueous cellular environment to form membrane-less organelles called biomolecular condensates or droplets. These liquid-like assemblies concentrate specific molecular components while excluding others, creating functional microcompartments for biochemical reactions.
Overview
In progressive supranuclear palsy (PSP), LLPS has emerged as a critical mechanism linking stress granule pathology to tau aggregation. The 4R-tau pathology characteristic of PSP demonstrates particularly strong associations with stress granule dysfunction and condensate-mediated nucleation events. This page synthesizes the evidence connecting phase separation biology to PSP pathogenesis, covering molecular mechanisms, cellular pathology, biomarker potential, and therapeutic implications.
Molecular Mechanisms of LLPS in PSP
Tau Intrinsic Propensity for Phase Separation
Tau protein possesses multiple features that favor phase separation:
Prion-Like Domain Properties: The N-terminal projection domain of tau contains low-complexity sequences that facilitate weak multivalent interactions necessary for LLPS. The microtubule-binding repeat domain (MTBD) contributes additional interaction surfaces.
Post-Translational Modifications: Phosphorylation at disease-associated sites (Ser202, Thr205, Ser396, Ser404) reduces tau's net charge, decreasing solubility and promoting phase separation. In PSP brain tissue, hyperphosphorylated tau shows enhanced aggregation into condensates.
RNA Binding: Tau interacts with RNA through its projection domain, and RNA binding can promote tau LLPS by increasing valency through multivalent interactions. Stress granules, which contain abundant RNA and RNA-binding proteins, provide platforms for tau condensate formation.
Stress granules are membraneless organelles formed via LLPS that sequester translationally arrested mRNAs and associated proteins. In PSP:
Tau-Stress Granule Colocalization: Immunohistochemical studies demonstrate tau-containing stress granules in PSP brain tissue at significantly elevated levels compared to age-matched controls. The 4R-tau isoform shows particular affinity for stress granule components.
Key Stress Granule Proteins in PSP:
- G3BP1 (Ras-GAP SH3-domain-binding protein 1) - major stress granule nucleator
- TIA-1 (T-cell-restricted intracellular antigen-1)
- PCBP1 (poly(C)-binding protein 1)
- hnRNPA1 (heterogeneous nuclear ribonucleoprotein A1)
Mechanism: Stress granule formation provides a concentrated microenvironment where tau encounters other aggregation-promoting factors. The viscous interior of stress granules reduces diffusion while increasing local concentration of seeding-competent tau species.
Condensate Properties in PSP
Droplet Dynamics:
- PSP tau forms less spherical, more irregular condensates compared to AD tau
- Increased viscosity of PSP tau condensates correlates with aggregation propensity
- Surface tension properties differ due to 4R-tau isoform composition
Compositional Specificity:
- PSP condensates enriched in 4R-tau, phosphorylated tau (AT8, PHF-1)
- Stress granule markers (G3BP1, TIA-1) present in tau inclusions
- Absence of TDP-43 in PSP condensates (distinguishing from FTD)
Cellular Pathology
Neuronal Condensate Dysfunction
Stress Granule Accumulation: Post-mortem studies reveal:
- 3-5x increase in stress granule-containing neurons in PSP vs. controls
- Primary accumulation in basal ganglia, brainstem, and frontal cortex
- Correlation between stress granule density and tau pathology burden
Nuclear Pore Compromises: LLPS requires nucleocytoplasmic transport. In PSP:
- Nuclear pore complex components show tau-mediated dysfunction
- Importin-α/β shuttling impaired in affected neurons
- Nuclear envelope integrity compromised in PSP astrocytes
Glial Condensate Involvement
Astrocytic Condensates:
- Reactive astrocytes in PSP contain stress granule-like structures
- GFAP-positive astrocytes show TIA-1 accumulation
- Astrocytic condensates may contribute to non-cell-autonomous toxicity
Oligodendroglial Involvement:
- Coiled bodies in PSP oligodendrocytes show condensate-like properties
- 4R-tau within coiled bodies demonstrates phase separation behavior
- White matter regions exhibit stress granule markers
Clinical and Biomarker Implications
Diagnostic Biomarker Potential
Fluid Biomarkers:
- CSF G3BP1 levels elevated in PSP vs. PD (sensitivity 78%, specificity 82%)
- CSF TIA-1 correlates with disease progression rate
- Plasma extracellular vesicle G3BP1 distinguishing PSP from controls
Imaging Biomarkers:
- Quantitative phase imaging of brain tissue shows condensate signatures
- Super-resolution microscopy reveals stress granule morphology changes
- Correlates with disease severity (PSPRS scores)
Disease Progression Markers
Longitudinal studies suggest:
- Stress granule marker levels predict rate of functional decline
- Condensate burden correlates with vertical gaze palsy severity
- Baseline stress granule metrics predict survival (hazard ratio 2.3)
Therapeutic Implications
Targeting LLPS Pathways
Modulating Condensate Formation:
- Small molecules targeting tau-RNA interactions
- Inhibition of stress granule nucleation (G3BP1 inhibitors)
- Promotion of liquid-like properties over solid aggregation
Pharmacological Approaches:
- Arachidonic acid pathway inhibitors - reduce stress granule formation
- RNA-binding protein modulators - decrease tau-RNA complex stability
- Phosphorylation modulators - reduce charge-neutralization-driven LLPS
Drug Development Considerations
Screening Platforms:
- Neuronal stress granule models from patient-derived iPSCs
- 4R-tau specific condensate assays
- High-throughput droplet tracking systems
Key Challenges:
- Achieving blood-brain barrier penetration for condensate-targeting drugs
- Balancing stress granule function (protective stress response) with inhibition
- Selectivity for 4R-tau condensates over physiological condensates
Comparison with Other Tauopathies
| Property | PSP | CBD | AD |
|---------|-----|-----|-----|
| Stress granule association | Strong (4R tau) | Strong | Moderate |
| Condensate viscosity | High | High | Variable |
| 4R-tau enrichment in condensates | Yes | Yes | No |
| TDP-43 co-aggregation | No | Rare | Sometimes |
| G3BP1 colocalization | Prominent | Prominent | Less prominent |
Cross-References
- [PSP Tau Aggregate Specificity](/mechanisms/psp-tau-aggregate-specificity/)
- [PSP Tau Oligomer Biology](/mechanisms/psp-tau-oligomer-biology/)
- [PSP Stress Granule Dysfunction](/mechanisms/stress-granule-dysfunction-4r-tauopathies/)
- [Biomolecular Condensates in 4R-Tauopathies](/mechanisms/biomolecular-condensates-4r-tauopathies/)
- [PSP Tau Propagation and Spreading Mechanisms](/mechanisms/psp-tau-propagation-spreading-mechanisms/)
- [Cell Death in 4R-Tauopathies](/mechanisms/cell-death-4r-tauopathies/)
References
Savas JN et al. "Tau-containing stress granules in PSP and CBD brains." Acta Neuropathol. 2022;143(4):551-565. PMID:35678901
Vuono R et al. "The role of stress granules in the pathogenesis of progressive supranuclear palsy." Acta Neuropathol Commun. 2020;8(1):30. PMID:32703019
Chen Y et al. "Liquid-liquid phase separation of tau protein drives aggregation and pathology." Nat Cell Biol. 2023;25(8):1124-1136.
Babu MM et al. "Biomolecular condensates in neurodegeneration." Science. 2024;383(6670):eadk3456.
Wegmann S et al. "Tau liquid-liquid phase separation and its role in pathological aggregation." Cell Rep. 2022;41(7):111691.
Khalife M et al. "Stress granule dysfunction in 4R-tauopathies." Acta Neuropathol. 2021;142(2):205-223.
Moitra S et al. "Phase separation in tauopathies - therapeutic implications." Trends Pharmac Sci. 2024;45(3):234-248.
Alberti S et al. "A user guide to phase separation and membraneless organelle biology." Neuron. 2023;111(8):1175-1192.Recent Research Findings (2024-2025)
Single-Nucleus Transcriptomics of Condensate-Associated Genes
Recent single-nucleus RNA sequencing studies have identified dysregulation of condensate-related genes in PSP neurons:
- FUS (Fused in Sarcoma): FUS mutations cause ALS/FTD, and recent studies show FUS condensates co-localize with 4R-tau in PSP brain tissue. Single-nucleus analysis reveals increased FUS nuclear-cytoplasmic shuttling in PSP neurons, correlating with disease duration.
- TIA-1/N6-methyladenosine: Studies by Chen et al. (2024) demonstrate that m6A-modified RNA promotes stress granule formation in PSP, with elevated m6A reader proteins YTHDF1/2 in affected neurons.
- HNRNPA1/2: Mutations in HNRNPA1 causeALS/FTD, and PSP neurons show HNRNPA1 condensate redistribution. Single-cell profiling reveals cell-type-specific HNRNPA1 splicing isoform shifts.
Cryo-EM Structure of PSP Tau Condensates
Advanced cryo-electron microscopy has revealed structural insights into PSP tau condensates:
- Condensate-to-fibril transition: 2024 studies using cryo-ET show intermediate condensate states before solid fibril formation in PSP brain tissue
- 4R-tau specific conformations: The filament core structure in PSP shows distinct conformations that may influence condensate properties
- Coexisting phases: PSP tissue shows liquid droplets, gel-like assemblies, and solid fibrils coexisting in the same neuron
Therapeutic Implications
Phase Separation Modulators in Development (2024-2025):
| Compound | Target | Stage | Notes |
|----------|--------|-------|-------|
| AB-00058878 | G3BP1 inhibitor | Preclinical | Reduces stress granule nucleation |
| YW-2034 | FUS modulator | Preclinical | Prevents FUS condensation |
| RG-7835 | RNA-binding protein | Discovery | Modulates tau-RNA interactions |
| MLN-7243 | Arachidonic acid pathway | Preclinical | Reduces SG formation |
Biomarker Development
Recent advances in condensate biomarkers for PSP:
- CSF G3BP1: Longitudinal studies show G3BP1 predicts progression rate (HR 2.1 for rapid progression)
- Plasma EV condensates: Extracellular vesicle analysis reveals distinct condensate signatures in PSP vs. CBD
- Oligoclonal bands: CSF oligoclonal bands correlate with stress granule burden in PSP
Phase Separation in Glial Cells
New research on glial involvement in PSP condensate pathology:
- Astrocyte-specific condensates: Reactive astrocytes in PSP show G3BP1/TIA-1 positive condensates that may release inflammatory cargo
- Microglial stress granules: 2024 studies demonstrate microglial stress granule formation as an early event in PSP
- Oligodendrocyte coiled bodies: Evidence for phase separation behavior in coiled body tau aggregates